Bluefish Pharmaceuticals rights issue provides SEK 50 million

The preliminary results of Bluefish Pharmaceutical's rights issue demonstrate that 4 614 160 shares have been subscribed.

Shares that were not subscribed with subscription rights will be distributed to shareholders who have subscribed for shares without preferential rights according to the principles described in the notice to the extraordinary general meeting. In addition, Färna Invest who had guaranteed the rights issue, will provide approximately SEK 13 million. Through the rights issue, Bluefish will receive gross offering proceeds of approximately SEK 50 million.

Through the rights issue, the number of shares in Bluefish is increased by 6 249 160 and the share capital is increased by SEK 1 251 114. After the rights issue, the company's share capital totals SEK 5 856 693 and the number of shares totals 29 253 460. The intention of the rights issue has been to secure the company's continued expansion of its product portfolio and launch into new markets.